JP2023533498A - Ｇｈｒｈアナログの低用量医薬組成物及びその使用 - Google Patents

Ｇｈｒｈアナログの低用量医薬組成物及びその使用 Download PDF

Info

Publication number
JP2023533498A
JP2023533498A JP2022580982A JP2022580982A JP2023533498A JP 2023533498 A JP2023533498 A JP 2023533498A JP 2022580982 A JP2022580982 A JP 2022580982A JP 2022580982 A JP2022580982 A JP 2022580982A JP 2023533498 A JP2023533498 A JP 2023533498A
Authority
JP
Japan
Prior art keywords
ghrh
trans
hexenoyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580982A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533498A5 (enExample
Inventor
クリスティアン・マルソレ
キリル・シンゲル
ダイアン・ポトヴィン
Original Assignee
ゼラテクノロジーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼラテクノロジーズ インコーポレイテッド filed Critical ゼラテクノロジーズ インコーポレイテッド
Publication of JP2023533498A publication Critical patent/JP2023533498A/ja
Publication of JP2023533498A5 publication Critical patent/JP2023533498A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022580982A 2020-07-05 2021-06-30 Ｇｈｒｈアナログの低用量医薬組成物及びその使用 Pending JP2023533498A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063048167P 2020-07-05 2020-07-05
US63/048,167 2020-07-05
PCT/CA2021/050904 WO2022006657A1 (en) 2020-07-05 2021-06-30 Low-dose pharmaceutical compositions of ghrh analogs and uses thereof

Publications (2)

Publication Number Publication Date
JP2023533498A true JP2023533498A (ja) 2023-08-03
JP2023533498A5 JP2023533498A5 (enExample) 2024-07-05

Family

ID=79553399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580982A Pending JP2023533498A (ja) 2020-07-05 2021-06-30 Ｇｈｒｈアナログの低用量医薬組成物及びその使用

Country Status (9)

Country Link
US (1) US20230270865A1 (enExample)
EP (1) EP4175661A4 (enExample)
JP (1) JP2023533498A (enExample)
KR (1) KR20230035600A (enExample)
CN (1) CN115884783A (enExample)
AU (1) AU2021306736A1 (enExample)
CA (1) CA3183299A1 (enExample)
IL (1) IL298991A (enExample)
WO (1) WO2022006657A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140249083A1 (en) * 2013-03-01 2014-09-04 Theratechnologies Inc. Formulations of growth hormone releasing factor (grf) molecules with improved stability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003229222B2 (en) * 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
US20080249017A1 (en) * 2007-04-04 2008-10-09 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
US8361964B2 (en) * 2011-04-21 2013-01-29 Theratechnologies Inc. Growth hormone releasing factor (GRF) analogs and uses thereof
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20200297817A1 (en) * 2019-03-22 2020-09-24 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
CA3037757A1 (en) * 2019-03-22 2020-09-22 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
EP3947426A4 (en) * 2019-03-29 2023-01-04 The General Hospital Corporation GHRH OR ANALOGUES FOR USE IN THE TREATMENT OF HEPATIC DISEASE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140249083A1 (en) * 2013-03-01 2014-09-04 Theratechnologies Inc. Formulations of growth hormone releasing factor (grf) molecules with improved stability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AIDS, vol. Vol.19, pp.1279-1287, JPN6025025770, 2005, ISSN: 0005631188 *

Also Published As

Publication number Publication date
AU2021306736A1 (en) 2023-01-19
WO2022006657A1 (en) 2022-01-13
CN115884783A (zh) 2023-03-31
EP4175661A1 (en) 2023-05-10
CA3183299A1 (en) 2022-01-13
KR20230035600A (ko) 2023-03-14
US20230270865A1 (en) 2023-08-31
IL298991A (en) 2023-02-01
EP4175661A4 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
EP2059260B1 (en) Pharmaceutical compositions comprising hGH for oral delivery
EP3912639A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
TW201605466A (zh) 具有經改善之安定性的藥學組成物（二）
US20220288096A1 (en) Compositions and methods for treating an aggregation disease or disorder
EP1631305B1 (en) Sincalide formulations
EP3528828B1 (en) Terlipressin composition for use in treating ascites
CN103347532A (zh) 口服可生物利用肽药物组合物及其方法
US20080261937A1 (en) Pharmaceutical compositions and method for treating pediatric hypogonadism
JP2010523501A (ja) Ｇｈｒｈ分子の医薬製剤
EP2961432B1 (en) Formulations of growth hormone releasing factor (grf) molecules with improved stability
NZ500777A (en) Pharmaceutical compositions comprising low solubility peptides
US20220378880A1 (en) Pharmaceutical compositions of ghrh analogs and uses thereof
JP3628713B2 (ja) 生理学的に活性なペプチドを含有する膣投与製剤
JP2024533274A (ja) 大きな生理活性物質及び賦形剤を含む医薬組成物
JP2023539699A (ja) 糖尿病を治療するためのイオン性液体製剤
US20230270865A1 (en) Low-dose pharmaceutical compositions of ghrh analogs and uses thereof
CA3037757A1 (en) Pharmaceutical compositions of ghrh analogs and uses thereof
CN102552140B (zh) 罗格列酮的液体组合物
CA2623477C (en) Compositions and method for treating pediatric hypogonadism
CN109044980B (zh) 生长抑素冻干粉针剂药物组合物及其制备方法
JP4880845B2 (ja) Ｇｒｆ含有凍結乾燥薬剤組成物
CN116635023A (zh) 用于治疗糖尿病的离子液体制剂
CN101155584A (zh) 给药伊沙匹隆的方法
JPH0597680A (ja) グリチルリチン坐剤
JPH10226650A (ja) グリチルリチン経口投与製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260310